Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | HINT1 | P49773 | 4/20 | 0.57 |
| ▸ | NT5E | P21589 | 2/20 | 0.57 |
| ▸ | PNP | P00491 | 2/20 | 0.56 |
| ▸ | CD99 | P14209 | 1/20 | 0.55 |
| ▸ | GSK3A | P49840 | 2/20 | 0.54 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| F-Arag SCHEMBL9489885 | 1.00 | PDE2A (0.64) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| F-Arag SCHEMBL12150772 | 1.00 | PDE2A (0.64) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| F-Arag SCHEMBL16656455 | 1.00 | PDE2A (0.64) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| F-Arag SCHEMBL14163604 | 1.00 | PDE2A (0.64) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| F-Arag SCHEMBL12300492 | 1.00 | PDE2A (0.64) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| F-Arag SCHEMBL236684 | 1.00 | PDE2A (0.64) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| F-Arag SCHEMBL35286 | 1.00 | PDE2A (0.64) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| F-Arag SCHEMBL20581034 | 1.00 | PDE2A (0.64) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| F-Arag SCHEMBL21625251 | 1.00 | PDE2A (0.64) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| F-Arag F-18 SCHEMBL29373858 | 1.00 | PDE2A (0.64) | PDE2AADORA3ADORA2AADORA1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1418 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| EP-4555086-A1 | OLIGONUCLEOTIDES FOR ADAR-MEDIATED RNA EDITING AND USE THEREOF | ProQR Therapeutics II B.V. (NL) | 2025-05-21 | — | — | EP | claimed |
| WO-2025081544-A1 | PURINE NUCLEOSIDE PHOSPHORYLASE MUTANT AND PREPARATION METHOD FOR 2'-FLUORO NUCLEOSIDE | 吉林凯莱英制药有限公司 | 2025-04-24 | — | — | WO | claimed |
| WO-2025081545-A1 | PYRIMIDINE NUCLEOSIDE PHOSPHORYLASE MUTANT AND PREPARATION METHOD FOR 2'-FLUORO NUCLEOSIDE | 吉林凯莱英制药有限公司 | 2025-04-24 | — | — | WO | claimed |
| EP-4379052-A2 | MRNA PURIFICATION BY TANGENTIAL FLOW FILTRATION | Ethris GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| WO-2024013361-A1 | OLIGONUCLEOTIDES FOR ADAR-MEDIATED RNA EDITING AND USE THEREOF | PROQR THERAPEUTICS II B.V. (NL) | 2024-01-18 | — | — | WO | claimed |
| EP-4306643-A2 | PLASMID CONTAINING A SEQUENCE ENCODING AN MRNA WITH A SEGMENTED POLY(A) TAIL | ethris GmbH (DE) | 2024-01-17 | — | — | EP | claimed |
| EP-4271389-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| CN-115725535-B | N-deoxyribotransferase and application thereof in preparation of deoxynucleosides | 杭州珲益生物科技有限公司 | 2023-06-06 | — | — | CN | claimed |
| CN-115725535-A | N-deoxyribotransferase and its application in preparing deoxynucleoside | 杭州珲益生物科技有限公司 | 2023-03-03 | — | — | CN | claimed |
| EP-2010659-A2 | KITS AND METHODS FOR GENERATING 5' CAPPED RNA | Epicentre Technologies (US) | 2009-01-07 | — | — | EP | claimed |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-15 | — | — | US | claimed |
| WO-2007120863-A2 | KITS AND METHODS FOR GENERATING 5' CAPPED RNA | EPICENTRE TECHNOLOGIES (US) | 2007-10-25 | — | — | WO | claimed |
| EP-1395266-B1 | USE OF ANTIVIRAL NUCLEOSIDE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HEPATITIS C INFECTIONS | HOFFMANN LA ROCHE (CH) | 2006-10-04 | — | — | EP | claimed |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | MERCK SHARP & DOHME LLC | 2004-06-10 | — | — | US | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| EP-1395266-A1 | ANTIVIRAL NUCLEOSIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-10 | — | — | EP | claimed |
| US-6660721-B2 | Treatment or prophylaxis of hepatitis C virus infections; viricides | HOFFMANN-LA ROCHE INC. | 2003-12-09 | — | — | US | claimed |
| US-20030083307-A1 | Anti-HCV nucleoside derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2003-05-01 | — | — | US | claimed |
| WO-2002094289-A1 | ANTIVIRAL NUCLEOSIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | PDE2A 878/4885ADORA3 95/4885ADORA2A 103/4885 |
| US-20030083307-A1 | Anti-HCV nucleoside derivatives | HAVCR2, EIF2AK2, NSUN2 | PDE2A 1477/4885ADORA3 120/4885ADORA2A 167/4885 |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | PDE2A 2926/4885ADORA3 4335/4885ADORA2A 3761/4885 |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | NSUN2, NSUN3, POLRMT | PDE2A 1392/4885ADORA3 304/4885ADORA2A 395/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | PDE2A 878/4885ADORA3 95/4885ADORA2A 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.